The company's buffering agent is naturally drawn to the most acidic areas of the body. Since tumors actively export acid, they create a "magnet" for the therapy. This approach leverages basic chemical kinetics for targeting, bypassing the need for complex biological receptors and acting as an upstream solution.
Previous human trials using oral sodium bicarbonate to buffer tumor acidity failed not because the biology was wrong, but because patients couldn't tolerate the required doses, leading to GI issues and non-adherence. Dive's transdermal approach bypasses the gut, solving a simple delivery challenge for a well-established biological target.
The company's core technology was first used to buffer lactic acidosis for athletic performance. After proving they could effectively modulate pH, they asked "where does pH matter most biologically?" This led them to the long-understood but hard-to-drug problem of the acidic tumor microenvironment, a much larger market.
For decades, tumor acidity was considered a mere consequence of metabolic activity (the Warburg effect). The modern understanding underpinning Dive’s strategy is that this acidity is a causal factor that actively drives tumor invasion, treatment resistance, and immune suppression, making it a viable therapeutic target.
Instead of going directly into high-risk oncology trials, Dive validated its core mechanism—systemic pH modulation via a topical agent—in a 98-patient gout study. This provided human data on target engagement and safety, significantly de-risking its subsequent, more complex cancer program by answering a key question upfront.
While most immuno-oncology drugs target specific cellular pathways, Dive Biosciences targets the acidic tumor microenvironment itself. This is framed as a foundational "upstream checkpoint" that degrades the entire immune "ecology," suppressing every type of immune cell in the tumor's vicinity at once, rather than one receptor at a time.